ArticleFrontiers in microbiology2011
Fungal glucosylceramides: from structural components to biologically active targets of new antimicrobials.
Article in Frontiers in microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 59 citations in OpenAlex.
- Pilocarpine inhibitsMicrobiology spectrum · 2025Article
- The experimentally evolved fluconazole-resistant clade II isolates of Candidozyma auris exhibit a distinct lipid compositional landscape, highlighting intraclade sphingolipid heterogeneity.FEMS yeast research · 2025Article
- Article
- Semisynthetic Glycoconjugate Vaccine Candidates againstACS infectious diseases · 2024Article
- Semi-synthetic glycoconjugate vaccine candidate againstbioRxiv : the preprint server for biology · 2024Article
- Sphingolipid diversity in Candida auris: unraveling interclade and drug resistance fingerprints.FEMS yeast research · 2024Article
- Role of sphingolipids in the host-pathogen interaction.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2023Article
- Antibodies to Combat Fungal Infections: Development Strategies and Progress.Microorganisms · 2023Review
- Extracellular vesicles of Candida albicans regulate its own growth through the L-arginine/nitric oxide pathway.Applied microbiology and biotechnology · 2023Article
- Measurement of neutral ceramidase activity in vitro and in vivo.Analytical biochemistry · 2022Review
- Glycosphingolipids in Filamentous Fungi: Biological Roles and Potential Applications in Cosmetics and Health Foods.Frontiers in microbiology · 2021Review
- Reassessing therapeutic antibodies for neglected and tropical diseases.PLoS neglected tropical diseases · 2020Review
- Article
- Membrane Sphingolipids Regulate the Fitness and Antifungal Protein Susceptibility ofFrontiers in microbiology · 2019Article
- Peeling the onion: the outer layers of Cryptococcus neoformans.Memorias do Instituto Oswaldo Cruz · 2018Review
- Diversity of Cell Wall Related Proteins in Human Pathogenic Fungi.Journal of fungi (Basel, Switzerland) · 2017Article
- Fungal Glucosylceramide-Specific Camelid Single Domain Antibodies Are Characterized by Broad Spectrum Antifungal Activity.Frontiers in microbiology · 2017Article
- Article
- Sphingolipids as targets for treatment of fungal infections.Future medicinal chemistry · 2016Review
- Cryptococcal therapies and drug targets: the old, the new and the promising.Cellular microbiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first work reporting synthesis of glucosylceramide (cerebrin, GlcCer) by yeasts was published in 1930. During approximately 70 years members of this class of glycosphingolipids (GSL) were considered merely structural components of plasma membrane in fungi. However, in the last decade GlcCer was reported to be involved with fungal growth, differentiation, virulence, immunogenicity, and lipid raft architecture in at least two human pathogens. Fungal GlcCer are structurally distinct from their mammalian counterparts and enriched at the cell wall, which makes this molecule an effective target for antifungal activity of specific ligands (peptides and antibodies to GlcCer). Therefore, GSL are promising targets for new drugs to combat fungal diseases. This review discusses the most recent information on biosynthesis and role of GlcCer in fungal pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.